Treatment of Chemotherapy - Induced Peripheral Neuropathy: The Physicians Need Guidelines, the Patients Need Help


  • Krzysztof Brzezinsk Outpatient Pain Clinic, Institute of Rural Health, ul. Jaczewskiego 2, 20-090 Lublin, Poland



Chemotherapy induced peripheral neuropathy, neuropathy, neuropathic pain, cancer related pain, pain treatment, amitiptyline, gabapentin, oxycodone, treatment schedule, pain, tactile allodynia, brush allodynia.


 The aim of the study was to verify the effectiveness of two methods of introducing standard CIPN-treatment drugs into the therapy.

Materials and Methods: Group A included patients attending weekly appointments, while group B monthly. Standard treatment with amitriptyline, gabapentin (GAB), and oxycodone (OXY) was administered. In group A, the drugs were gradually introduced, while in group B - within one week. After a month and six months of treatment, the therapy effectiveness was assessed by examination of pain intensity (VAS), symptoms of peripheral neuropathy (sNCI-CTC), occurrence of tactile and brush allodynia, and the daily dose of GAB andOXY.

Results: Pain intensity during the study decreased from 5.59 to 2.9 and 2.76 in group A, and from 5.07 to 2.52 and 2.81 in group B. The sNCI-CTC values declined too and were, respectively. 1.9; 1.48; 1.34 in group A and 1.93; 1.52; 1.44 in group B. Tactile allodynia occurred in 15; 5; 5 group A patients and 18; 6; 5 group B patients. Brush allodynia decreased in group A (9; 5; 5) and B (11; 6; 5). The daily GAB dose was 0; 951.72; 927.41 in group A and 900.0; 900.0; 1000.0 in group B. The daily OXY dose was 0; 21.72; 22.07 in group A and 20.0; 20.0; 27.04 in group B; a statistically significant difference was found in the final stage.

The results do not allow recommendation of non-schematic treatment and they should be regarded as a preliminary study. Randomized trials are indispensable for assessment of advantages and drawbacks such treatment.


Stannard CF, Kalso E, Ballantyne J. Evidence-based chronic pain management. ISBN: 978-1-4051-5291-4. Wiley-Blackwell 2010.

Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007; 13: 2237-251.

Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289-305.

Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010; 150: 573-81.

Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85(suppl): 3-14.

Blyth FM, March LM, Brnabic AJ, Cousins MJ. Chronic pain and frequent use of health care. Pain 2004; 111(1-2): 51-8.

Grad R, Tamblyn R, McLeod PJ, Snell L, Illescas A, Boudreau D. Does knowledge of drug prescribing predict drug management of standardized patients in office practice? Med Educ 1997; 31: 132-7.

Dworkin RH, Panarites CJ, Armstrong EP, Malone DC, Pham SV. Is treatment of postherpetic neuralgia in the community consistent with evidence-based recommendations? Pain 2012; 153(4): 869-75.

Cruccu G, Attal N. Do clinicians adhere to treatment recommendations for neuropathic pain? Pain 2012; 153(4): 740-1.

Vielvoye-Kerkmer A, Mattern C, Uitendaal MP. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. J Pain Symptom Manage 2000; 19: 185-92.

Mystakidou K, Befon S, Tsilika E, Dardoufas K, Georgaki S, Vlahos L. Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids. Oncology 2002; 62: 9-16.

Mystakidou K, Parpa E, Tsilika E, et al. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers. J Pain 2004; 5: 119-32.

Ripamonti C, Fagnoni E, Campa T, Brunelli C, De Conno F. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 2006; 14: 400-407.

Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. Journal of the Peripheral Nervous System 2008; 13: 27-46.

Paice JA. Chronic treatment-related pain in cancer survivors. Pain 2011; 152: 84-89.

Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain 2008; 138: 343-53.

Hansson PT, Dickenson AH. Pharmacological treatment of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies. Pain 2005; 113: 251-4.

Smith EM, Bakitas MA, Homel P, et al. Preliminary assessment of a neuropathic pain treatment and referral algorithm for patients with cancer. J Pain Symptom Manage 2011; 42: 822-38.

Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113-20.




How to Cite

Brzezinsk, K. . (2012). Treatment of Chemotherapy - Induced Peripheral Neuropathy: The Physicians Need Guidelines, the Patients Need Help. Journal of Cancer Research Updates, 1(1),  108–113.